title: [Breast cancer after Hodgkin disease].
abstract: Secondary breast cancer represents 6 to 9% of secondary neoplasia after treatments for Hodgkin Disease (HD). Mostly, they appear 10 years after the end of treatments for HD. The most important risk factors are mantle field irradiation and the young age. The means of screening and treatments are still in discussion. We report a case of bilateral intraductal and invasive carcinoma that occurred 16 years after treatments for HD, developing its particularities in diagnosis and treatment, particularly place of conservative treatments and sentinel lymph node biopsy.
authors.affiliation: Unité de sénologie, pôle de gynécologie-obstétrique, CHRU de Strasbourg, avenue Molière, 67200 Strasbourg cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Guillaume
authors.forename: B
authors.initials: B
authors.lastname: Morin
authors.forename: C
authors.initials: C
authors.lastname: Mathelin
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D008408:Mastectomy; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011182:Postoperative Care; D019651:Plastic Surgery Procedures; D012307:Risk Factors; D021701:Sentinel Lymph Node Biopsy; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen